Gilead’s Response to COVID-19

Gilead is focused on deploying our resources and decades of antiviral expertise to help patients and communities fighting the COVID-19 pandemic. As a pioneer and leader in antiviral drug development, Gilead developed the first antiviral drug approved to treat COVID-19 and continues to invest in this medicine and research that will prepare us for emerging pandemic threats.  

Gilead continues to collaborate with global health authorities, government agencies, healthcare systems, academic institutions, nonprofit organizations, and individual researchers and clinicians to share and update information and to bring the full weight of our science to help end this pandemic.  

Enabling Access

Learn more about our access partnerships

Read about how we helped respond to the COVID-19 pandemic responsibly

For More Information

Please contact Gilead via email with any questions by clicking here.

Last Updated: January. 7, 2024